Navigation Links
New anti-HIV drug target identified by University of Minnesota researchers
Date:12/18/2013

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Complete findings are printed in today's issue of the Journal of Virology.

The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2'-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis. Lethal mutagenesis annihilates HIV by causing it to mutate to the point of extinction.

The compound 3-deazauridine stopped HIV by creating so many mutations in the virus that the virus was no longer able to spread throughout the body by infecting other cells. The other compounds caused early termination of HIV DNA synthesis, again preventing the virus from being able to reproduce. Studies prior to this one determined certain ribonucleosides analogs impact HIV DNA synthesis, a process called reverse transcription. The extent to which they worked was not previously known.

"It's a counterintuitive finding," said University of Minnesota virologist Louis Mansky, Ph.D. "These ribonucleoside analogs were not generally thought to be associated with affecting HIV DNA synthesis a critical step in virus replication. We don't yet know all the details for how these particular compounds stop the virus in its path."

The research, if translatable, will provide a potentially cost-effective and fresh treatment option to counter HIV's rapid evolution and treat HIV resistance to currently approved anti-HIV drugs. Anti-HIV ribonucleoside analogs are less expensive to create in a laboratory than deoxyribonucleoside analogs, which are key in drugs currently used to stop HIV replication and cell spread. Additionally, the similarity of ribonucleoside analogs to d
'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Potential drug molecule shows enhanced anti-HIV activity
2. New drug-screening method yields long-sought anti-HIV compounds
3. Anti-HIV drug use during pregnancy does not affect infant size, birth weight
4. Going against the flow: Halting atherosclerosis by targeting micro RNA
5. Targeted synthesis of natural products with light
6. Glucose: Potential new target for combating annual seasonal influenza
7. Stealth maneuver allows nectar bats to target insect prey
8. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
9. Targeted treatment can significantly reduce relapse in children with AML leukemia
10. New target identified for preventing bone destruction in diseases such as arthritis and cancer
11. Fruit pest targeted by genomic research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... 16, 2011The American Association for the Advancement of ... Srivastava, MD, a Fellow for his efforts to ... directs cardiac and stem cell research at Gladstone, ... research efforts are focused in the areas of ...
... (OGI) has awarded two research facilities with $10,000 each ... the work of Ontario researchers., ,The two recipients ... The Hospital for Sick Children (SickKids) in Toronto and ... StemCore Laboratories based at the Ottawa Hospital Research Institute. ...
... animal, from a blue whale to a human being, ... the cells in its body will die without reproducing; ... the next generation. How could the extreme degree ... aren,t all creatures unicellular individualists determined to pass on ...
Cached Biology News:Gladstone scientist Deepak Srivastava named fellow of the AAAS 22 research facilities awarded technology seeding grants 2Close family ties keep microbial cheaters in check, study finds 2Close family ties keep microbial cheaters in check, study finds 3Close family ties keep microbial cheaters in check, study finds 4Close family ties keep microbial cheaters in check, study finds 5
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... BALTIMORE, March 24, 2011 Champions Biotechnology, Inc. ... a technology collaboration agreement with Cephalon, Inc. in ... on two proprietary chemical compounds, CEP-32496, an inhibitor ... ALK-FAK inhibitor, provided by Cephalon to determine the ...
... Calif., March 24, 2011 ValGenesis, Inc., an ... solutions, today announced the availability of its industry-proven ... (SaaS) offering hosted on MUSA,s Validated Cloud. ... Lifecycle Management solution accessible via the Internet through ...
... Rules-Based Medicine, Inc. (RBM), a leading provider of innovative ... OncologyMAP ® , a powerful tool developed at the ... Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... on biological pathways that could hold the key to ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
... protein assay kit I provides reagents and a ... presence of reducing agents and detergents. The RC ... kit includes reagents and standards sufficient for 500 ... ml RC reagent II, 250 ml alkaline copper ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... three-color reagent kit for determining the absolute ... blood samples, mobilized peripheral blood samples, and ... a total nucleated cell count and a ... is designed for use in the BD ...
... Rhodopsin is a glycoprotein which is ... and reptiles. The rhodopsin protein is present ... Immunogen: Membrane preparation from ... This antibody specifically labels the axons andsynaptic ...
Biology Products: